Case Study

Development And Manufacturing Of A Fab Fragment For Clinical Trials

Laboratory bioprocess iStock-1144377258

Balancing Speed and Risk to Meet an Aggressive Timeline

In this customer case study, we are focusing on our collaboration with Acticor Biotech, a spin-off of Inserm, the French National Institute of Health and Medical Research, which is advancing an innovative drug for the treatment of the acute phase of ischemic stroke.

Acticor selected MilliporeSigma’s BioReliance® End-to-End Solutions for process development and GMP manufacturing of a Fab fragment to support clinical trials. The project timeline allowed only 18 months to get from the cell line to clinical batch manufacturing. A strategic approach to risk management was leveraged to help meet an aggressive timeline.

VIEW THE CASE STUDY!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Bioprocess Online